Foundational therapy for heart failure and a reduced ejection fraction consists of a
combination of an angiotensin receptor–neprilysin inhibitor, a beta‐blocker, a …

Treatment with β-blockers is the main strategy for managing patients with heart failure and
reduced ejection fraction because of their ability to reverse the neurohumoral effects of the …

Abstract Aims Quality indicators (QIs) are tools to improve the delivery of evidence-base
medicine. In 2017, the European Society of Cardiology (ESC) Association for Acute …

Increased left ventricular dilation and reduced systolic function are consistently associated
with a poor prognosis and worse clinical outcomes. In this review, we discuss the …

β-Adrenergic receptors (βARs) regulate normal and pathophysiological heart function
through their impact on contractility. βARs are also regulators of immune function where they …

Aims β-blockers are widely used in therapy for heart failure and hypertension. β-blockers are
also known to evoke additional diversified pharmacological and physiological effects in …

Chronic heart failure is one of the common causes of hospitalization and death. Pulmonary
congestion is the common disease feature of patients with chronic heart failure, which could …

Purpose Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have been shown in
randomized controlled trials to improve cardiovascular, metabolic, and renal outcomes in …

Skin cancer is the most common malignancy worldwide and is rapidly rising in incidence,
representing a significant public health challenge. The β-blocker, carvedilol, has shown …

Atrial fibrillation (AF) is one of the main cardiac arrhythmias associated with higher risk of
cardiovascular morbidity and mortality. AF can cause adverse symptoms and reduced …